In a prospective study of more than 1,800 patients at 31 clinical centers in the US, the PancreaSeq test developed at the University of Pittsburgh surpassed currently used guidelines for correctly classifying potentially cancerous pancreatic cysts.
In a prospective study of more than 1,800 patients at 31 clinical centers in the US, the PancreaSeq test developed at the University of Pittsburgh surpassed currently used guidelines for correctly classifying potentially cancerous pancreatic cysts.
PancreaSeq is a product of the Molecular & Genomic Pathology Laboratory at the University of Pittsburgh Medical Center.